325 related articles for article (PubMed ID: 36575477)
1. Whole body FDG PET/MR for progression free and overall survival prediction in patients with relapsed/refractory large B-cell lymphomas undergoing CAR T-cell therapy.
Sjöholm T; Korenyushkin A; Gammelgård G; Sarén T; Lövgren T; Loskog A; Essand M; Kullberg J; Enblad G; Ahlström H
Cancer Imaging; 2022 Dec; 22(1):76. PubMed ID: 36575477
[TBL] [Abstract][Full Text] [Related]
2. [Prognostic value of pretreatment (18)F-FDG PET-CT for patients with advanced diffuse large B-cell lymphoma].
Ding CY; Guo Z; Sun J; Yang WP; Li TR
Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):528-533. PubMed ID: 30060362
[No Abstract] [Full Text] [Related]
3. Evaluation of the prognostic value of different methods of calculating the tumour metabolic volume with
Guzmán Ortiz S; Mucientes Rasilla J; Vargas Núñez JA; Royuela A; Navarro Matilla B; Mitjavila Casanovas M
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(6):340-346. PubMed ID: 32646783
[TBL] [Abstract][Full Text] [Related]
4. [
Gui J; Li M; Xu J; Zhang X; Mei H; Lan X
Eur J Nucl Med Mol Imaging; 2024 Mar; ():. PubMed ID: 38467921
[TBL] [Abstract][Full Text] [Related]
5. Combination of Deauville score and quantitative positron emission tomography parameters as a predictive tool of anti-CD19 chimeric antigen receptor T-cell efficacy.
Guidetti A; Dodero A; Lorenzoni A; Pizzamiglio S; Argiroffi G; Chiappella A; Bagnoli F; Marasco V; Carniti C; Monfrini C; Seregni E; Pennisi M; Verderio P; Alessi A; Corradini P
Cancer; 2023 Jan; 129(2):255-263. PubMed ID: 36385707
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of combined MTV and ADC derived from baseline FDG PET/MRI in aggressive non-Hodgkins lymphoma.
Husby T; Johansen H; Bogsrud TV; Hustad KV; Evensen BV; Boellaard R; Giskeødegård GF; Fagerli UM; Eikenes L
BMC Cancer; 2022 Nov; 22(1):1117. PubMed ID: 36319985
[TBL] [Abstract][Full Text] [Related]
7. [Prognostic value of pretreatment (18)F-FDG PET-CT metabolic parameters in patients with advanced extranodal NK/T cell lymphoma].
Wu LL; Liang JH; Wang L; Xu W; Ding CY
Zhonghua Zhong Liu Za Zhi; 2019 Nov; 41(11):831-836. PubMed ID: 31770850
[No Abstract] [Full Text] [Related]
8. Baseline [
Marchal E; Palard-Novello X; Lhomme F; Meyer ME; Manson G; Devillers A; Marolleau JP; Houot R; Girard A
Eur J Nucl Med Mol Imaging; 2024 Jan; 51(2):481-489. PubMed ID: 37721580
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma.
Zhou M; Chen Y; Huang H; Zhou X; Liu J; Huang G
Oncotarget; 2016 Dec; 7(50):83544-83553. PubMed ID: 27835875
[TBL] [Abstract][Full Text] [Related]
10. Combined pre-treatment MRI and 18F-FDG PET/CT parameters as prognostic biomarkers in patients with cervical cancer.
Miccò M; Vargas HA; Burger IA; Kollmeier MA; Goldman DA; Park KJ; Abu-Rustum NR; Hricak H; Sala E
Eur J Radiol; 2014 Jul; 83(7):1169-1176. PubMed ID: 24767630
[TBL] [Abstract][Full Text] [Related]
11. Conventional and novel [
Leithner D; Flynn JR; Devlin SM; Mauguen A; Fei T; Zeng S; Zheng J; Imber BS; Hubbeling H; Mayerhoefer ME; Bedmutha A; Luttwak E; Corona M; Dahi PB; Luna de Abia A; Landego I; Lin RJ; Palomba ML; Scordo M; Park JH; Tomas AA; Salles G; Lafontaine D; Michaud L; Shah GL; Perales MA; Shouval R; Schöder H
J Hematol Oncol; 2024 Apr; 17(1):21. PubMed ID: 38649972
[TBL] [Abstract][Full Text] [Related]
12. Imaging Biomarkers to Predict Outcomes in Patients With Large B-Cell Lymphoma With a Day 28 Partial Response by
Lutfi F; Goloubeva O; Kowatli A; Gryaznov A; Kim DW; Dureja R; Margiotta P; Matsumoto LR; Bukhari A; Ahmed N; Mushtaq MU; Law JY; Lee ST; Kocoglu MH; Atanackovic D; Yared JA; Hardy NM; McGuirk JP; Rapoport AP; Chen W; Dahiya S
Clin Lymphoma Myeloma Leuk; 2023 Oct; 23(10):757-763. PubMed ID: 37453865
[TBL] [Abstract][Full Text] [Related]
13. Prognostic superiority of the National Comprehensive Cancer Network International Prognostic Index over pretreatment whole-body volumetric-metabolic FDG-PET/CT metrics in diffuse large B-cell lymphoma.
Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
Eur J Haematol; 2015 Jun; 94(6):532-9. PubMed ID: 25311082
[TBL] [Abstract][Full Text] [Related]
14. Prediction of tumour grade and survival outcome using pre-treatment PET- and MRI-derived imaging features in patients with resectable pancreatic ductal adenocarcinoma.
Dunet V; Halkic N; Sempoux C; Demartines N; Montemurro M; Prior JO; Schmidt S
Eur Radiol; 2021 Feb; 31(2):992-1001. PubMed ID: 32851447
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Impact of 18F-FDG PET/CT in Patients With Aggressive B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T Cells.
Sesques P; Tordo J; Ferrant E; Safar V; Wallet F; Dhomps A; Brisou G; Bouafia F; Karlin L; Ghergus D; Golfier C; Lequeu H; Lazareth A; Vercasson M; Hospital-Gustem C; Schwiertz V; Choquet M; Sujobert P; Novelli S; Mialou V; Hequet O; Carras S; Fouillet L; Lebras L; Guillermin Y; Leyronnas C; Cavalieri D; Janier M; Ghesquières H; Salles G; Bachy E
Clin Nucl Med; 2021 Aug; 46(8):627-634. PubMed ID: 34115706
[TBL] [Abstract][Full Text] [Related]
16. Volume-based quantitative FDG PET/CT metrics and their association with optimal debulking and progression-free survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery.
Vargas HA; Burger IA; Goldman DA; Miccò M; Sosa RE; Weber W; Chi DS; Hricak H; Sala E
Eur Radiol; 2015 Nov; 25(11):3348-53. PubMed ID: 25916387
[TBL] [Abstract][Full Text] [Related]
17.
Mi L; Zhao Y; Zhao X; Yin F; Yin X; Li N; Shi J; Han X; Duan X; Zhao M; Han G; Wang J
Cancer Biother Radiopharm; 2021 Oct; 36(8):662-671. PubMed ID: 32783634
[No Abstract] [Full Text] [Related]
18. Prognostic value of metabolic tumour volume on baseline
Shagera QA; Cheon GJ; Koh Y; Yoo MY; Kang KW; Lee DS; Kim EE; Yoon SS; Chung JK
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1417-1427. PubMed ID: 30941463
[TBL] [Abstract][Full Text] [Related]
19. High Metabolic Tumour Volume on 18-Fluorodeoxyglucose Positron Emission Tomography Predicts Poor Survival from Neuroendocrine Neoplasms.
Chan DL; Bernard EJ; Schembri G; Roach PJ; Johnson M; Pavlakis N; Clarke S; Bailey DL
Neuroendocrinology; 2020; 110(11-12):950-958. PubMed ID: 31711058
[TBL] [Abstract][Full Text] [Related]
20. Prognostic impact of total metabolic tumor volume in large B-cell lymphoma patients receiving CAR T-cell therapy.
Iacoboni G; Simó M; Villacampa G; Catalá E; Carpio C; Díaz-Lagares C; Vidal-Jordana Á; Bobillo S; Marín-Niebla A; Pérez A; Jiménez M; Abrisqueta P; Bosch F; Barba P
Ann Hematol; 2021 Sep; 100(9):2303-2310. PubMed ID: 34236497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
